<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00183274</url>
  </required_header>
  <id_info>
    <org_study_id>MH65963</org_study_id>
    <secondary_id>R01MH065963</secondary_id>
    <nct_id>NCT00183274</nct_id>
  </id_info>
  <brief_title>Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR</brief_title>
  <official_title>Short-term Versus Long-term Treatment in Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of venlafaxine XR, randomized to either venlafaxine
      XR or placebo in preventing the relapse of generalized anxiety disorder after 6 months of
      treatment versus 12 months of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized anxiety disorder (GAD) is a highly prevalent, chronic psychiatric disorder.
      Despite the fact that GAD frequently demands prolonged treatment with medication, very little
      is known about the benefits of long-term treatment. GAD is characterized by 6 months or more
      of exaggerated worry and tension that is unfounded or much more severe than the normal
      anxiety most people experience. People with GAD are unable to relax and often suffer from
      insomnia. Venlafaxine XR, a drug used to treat depression, has been shown to be effective in
      the short-term treatment of GAD. However, its benefits over a course of more than 8 weeks
      have not been assessed. This study will evaluate the effectiveness of venlafaxine XR in
      treating GAD on a long-term basis and preventing the relapse of GAD after 6 months of
      treatment versus 12 months of treatment.

      Participants in this double-blind study will first receive 6 months of open-label treatment
      with venlafaxine XR. Upon completion of this initial phase, participants will be randomly
      assigned to either continue on venlafaxine XR or begin taking placebo. After 12 months,
      participants taking venlafaxine XR will be randomly assigned to continue on the drug or
      switch to placebo. Participants will have 22 study visits over at least 18 months. Follow-up
      visits will occur 24 months after enrollment. Relapse of GAD will be assessed with the
      Hamilton Anxiety Scale and Global Severity and Improvement Scale. A variety of methods,
      including questionnaires and standardized scales, will be used to assess secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Anxiety</measure>
    <time_frame>Measured at Months 6 (Open Label), 12 (Double-Blind), and 18 (Double-Blind Relapse)</time_frame>
    <description>Hamilton Rating Scale for Anxiety - The assessment of anxiety states by rating
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions, Severity of Illness</measure>
    <time_frame>Measured at Months 6 (Open Label), 12 (Double-Blind), 18 (Double-Blind, and 24 (Double-Blind Relapse)</time_frame>
    <description>The CGI provides an overall clinician-determined summary measure that takes into account a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Results of the &quot;Placebo After Placebo&quot; group in Phase 3 were not entered due to sample size limitations.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Open-Label Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Drug Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Drug-After-Drug Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Placebo-After-Drug Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Placebo-After-Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine XR</intervention_name>
    <description>Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d</description>
    <arm_group_label>Open-Label Group</arm_group_label>
    <arm_group_label>Double-Blind Drug Group</arm_group_label>
    <arm_group_label>Double-Blind Drug-After-Drug Group</arm_group_label>
    <other_name>selective serotonin and norepinephrine reuptake inhibitors</other_name>
    <other_name>Effexor</other_name>
    <other_name>Effexor XR</other_name>
    <other_name>Venlafaxine hydrochloride extended release</other_name>
    <other_name>Trevilor</other_name>
    <other_name>Lanvexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>six month intervention with placebo drug</description>
    <arm_group_label>Double-Blind Placebo Group</arm_group_label>
    <arm_group_label>Double-Blind Placebo-After-Drug Group</arm_group_label>
    <arm_group_label>Double-Blind Placebo-After-Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GAD diagnosis by structured interview

          -  Hamilton Anxiety Scale score of 18 or MORE

          -  Clinical Global Impressions Severity Scale score of at least 4

          -  Hamilton Depression Scale score of 18 or less

          -  Hamilton Depression Scale suicide item score less than 2

          -  Use of an effective form of contraception throughout the study

        Exclusion Criteria:

          -  Hypersensitivity to venlafaxine XR

          -  History of seizures

          -  Episode of major depressive disorder in the previous 6 months

          -  History of any psychotic illness, bipolar disorder, or dementia

          -  Substance abuse and dependence during the past 6 months

          -  Other anxiety disorders with the exception of social phobia as long as GAD is primary

          -  Regular use of anxiolytics or antidepressants within 7 days of study onset

          -  Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low
             dose usage of benzodiazepines will not prevent participation)

          -  Use of other psychotropic medication besides benzodiazepines during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Rickels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania, 3535 Market Street, Suite 670</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rickels K, Etemad B, Rynn MA, Lohoff FW, Mandos LA, Gallop R. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR. Psychother Psychosom. 2013;82(6):363-71. doi: 10.1159/000351410. Epub 2013 Sep 20.</citation>
    <PMID>24061331</PMID>
  </reference>
  <results_reference>
    <citation>Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010 Dec;67(12):1274-81. doi: 10.1001/archgenpsychiatry.2010.170.</citation>
    <PMID>21135327</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>December 14, 2012</results_first_submitted>
  <results_first_submitted_qc>October 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2016</results_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Karl Rickels</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>Chronic Mediation Treatment</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Placebo Controlled</keyword>
  <keyword>Venlafaxine XR</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Serotonin and Noradrenaline Reuptake Inhibitors</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Most patients (n=239) were recruited and seen by Penn research psychiatrists in 4 primary care practices; others (n=95) responded to media advertising (radio &amp; print ads) at the central clinic at the University of Pennsylvania</recruitment_details>
      <pre_assignment_details>7-day washout period of any psychoactive medication;other antidepressants and herbal products. Subject on certain medications, such as monamine oxidase inhibitor, investigational and antipsychotic drugs had to be off these medications for at least 30 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Open-Label</title>
          <description>Patients received 75mg - 225 mg of open-label venlafaxine XR for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Double-Blind Venlafaxine XR</title>
          <description>Responders to 6 months of open-label venlafaxine XR treatment were randomized to double-blind treatment in 60:40 ratio of drug to placebo</description>
        </group>
        <group group_id="P3">
          <title>Phase 2: Double-Blind Placebo</title>
          <description>Responders to 6 months of open-label venlafaxine XR treatment were randomized to double-blind treatment in a 60:40 ratio of drug to placebo</description>
        </group>
        <group group_id="P4">
          <title>Phase 3: Double-Blind Relapse Phase (Drug After Drug)</title>
          <description>Patients administered venlafaxine XR in phase 2 continued to take the drug during phase 3</description>
        </group>
        <group group_id="P5">
          <title>Phase 3: Double-Blind Relapse Phase (Placebo After Drug)</title>
          <description>Patients administered venlafaxine XR in Phase 2 were given a placebo in Phase 3</description>
        </group>
        <group group_id="P6">
          <title>Phase 3: Double-Blind Relapse Phase (Placebo After Placebo)</title>
          <description>Patients administered placebo in Phase 2 continued to take placebo during Phase 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: Open-Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158">110 dropouts during phase 1</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2: Double-Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This phase ended after 6 months. There were no longer participants in this phase.</participants>
                <participants group_id="P2" count="82">22 did not enter phase 2 due to lack of efficacy and withdrawal of consent</participants>
                <participants group_id="P3" count="54">22 did not enter phase 2 due to lack of efficacy and withdrawal of consent</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="56">8 lost to relapse, 18 lost to dropout</participants>
                <participants group_id="P3" count="11">29 lost to relapse, 14 lost to dropout</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 3: Double-Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">Phase 2 ended at the end of 12 months of study.</participants>
                <participants group_id="P3" count="0">Phase 2 ended at the end of 12 months of study.</participants>
                <participants group_id="P4" count="15">8 completed Phase 2 but did not enter phase 3</participants>
                <participants group_id="P5" count="34">8 completed Phase 2 but did not enter phase 3</participants>
                <participants group_id="P6" count="10">8 completed Phase 2 but did not enter phase 3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13">1 lost to relapse and 1 lost to dropout</participants>
                <participants group_id="P5" count="14">11 lost to relapse and 9 lost to dropout</participants>
                <participants group_id="P6" count="6">2 lost to relapse and 2 lost to dropout</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>334 participants were consented, but 64 withdrew consent and 2 deviated from protocol, resulting in 268 participants who entered the initial Phase 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Venlafaxine XR</title>
          <description>Venlafaxine XR flexible dose of 75 - 225 mg/d
Venlafaxine XR : All participants will take venlafaxine for 6 months. After this initial 6 months, participants who are not randomized to placebo will continue to take venlafaxine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.11" spread="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Anxiety</title>
        <description>Hamilton Rating Scale for Anxiety - The assessment of anxiety states by rating
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe.</description>
        <time_frame>Measured at Months 6 (Open Label), 12 (Double-Blind), and 18 (Double-Blind Relapse)</time_frame>
        <population>The primary efficacy analytic method was time-to-relapse analyses estimated using a discrete-time Cox proportional hazards model.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label: Venlafaxine XR</title>
            <description>A 6-month open label administration of flexible dose Venlafaxine XR that occurred between months 1 - 6 of study.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Venlafaxine XR</title>
            <description>A 6-month double-blind administration of Venlafaxine XR that occurred between months 7 - 12.</description>
          </group>
          <group group_id="O3">
            <title>Double-Blind Placebo</title>
            <description>A 6-month double-blind administration of placebo that occurred between months 7 - 12.</description>
          </group>
          <group group_id="O4">
            <title>Double-Blind Relapse Drug After Drug</title>
            <description>A 6-month double-blind administration of Venlafaxine XR that occurred between months 13 - 18.</description>
          </group>
          <group group_id="O5">
            <title>Double-Blind Relapse Placebo After Drug</title>
            <description>A 6-month double-blind administration of placebo that occurred between months 13 - 18.</description>
          </group>
          <group group_id="O6">
            <title>Double-Blind Placebo After Placebo</title>
            <description>A 6-month double-blind administration of placebo that occurred between months 13 - 18.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Anxiety</title>
          <description>Hamilton Rating Scale for Anxiety - The assessment of anxiety states by rating
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe.</description>
          <population>The primary efficacy analytic method was time-to-relapse analyses estimated using a discrete-time Cox proportional hazards model.</population>
          <units>HAM-A Rating Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="3.10"/>
                    <measurement group_id="O2" value="6.29" spread="5.44"/>
                    <measurement group_id="O3" value="11.35" spread="5.51"/>
                    <measurement group_id="O4" value="5.80" spread="4.95"/>
                    <measurement group_id="O5" value="8.42" spread="6.12"/>
                    <measurement group_id="O6" value="6.19" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions, Severity of Illness</title>
        <description>The CGI provides an overall clinician-determined summary measure that takes into account a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Results of the &quot;Placebo After Placebo&quot; group in Phase 3 were not entered due to sample size limitations.</description>
        <time_frame>Measured at Months 6 (Open Label), 12 (Double-Blind), 18 (Double-Blind, and 24 (Double-Blind Relapse)</time_frame>
        <population>The primary efficacy analytic method was time to relapse analyses estimated using a discrete time Cox proportional hazards model.Chisquare analyses were used to contrast relapse or responder rates. In the case of small cell sizes, Fisher exact test replaced chisquare analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Open-Label Venlafaxine XR</title>
            <description>A 6-month administration of Venlafaxine XR that occurred between months 1 - 6 of study.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Double-Blind Venlafaxine XR</title>
            <description>after receiving drug in phase 1, patients continued to receive drug in phase 2</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Double-Blind Placebo</title>
            <description>After receiving drug in Phase 1, patients began receiving placebo in phase 2</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Double-Blind Drug After Drug</title>
            <description>after receiving drug in phases 1 and 2, patients continued to receive drug in phase 3</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Placebo After Drug</title>
            <description>after receiving drug in phases 1 and 2, patients received placebo in phase 3</description>
          </group>
          <group group_id="O6">
            <title>Placebo After Placebo</title>
            <description>after receiving drug in phases 1 and placebo in phase 2, patients received placebo in phase 3</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions, Severity of Illness</title>
          <description>The CGI provides an overall clinician-determined summary measure that takes into account a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.
The CGI is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Results of the &quot;Placebo After Placebo&quot; group in Phase 3 were not entered due to sample size limitations.</description>
          <population>The primary efficacy analytic method was time to relapse analyses estimated using a discrete time Cox proportional hazards model.Chisquare analyses were used to contrast relapse or responder rates. In the case of small cell sizes, Fisher exact test replaced chisquare analysis.</population>
          <units>Severity Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.65"/>
                    <measurement group_id="O2" value="1.73" spread="1.27"/>
                    <measurement group_id="O3" value="2.64" spread="1.25"/>
                    <measurement group_id="O4" value="1.86" spread="1.01"/>
                    <measurement group_id="O5" value="2.25" spread="1.17"/>
                    <measurement group_id="O6" value="1.95" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Venlafaxine XR</title>
          <description>Adverse events were expected with venlafaxine XR. AEs were reported at least once by at least 5% of the study population for all patients who entered treatment. None of the adverse events that were expected or that occurred were considered serious or life threatening.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Decreased Orgasm</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Decreased Sex Drive</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Delayed Orgasm</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Faintness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Increased sweating</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Jitteriness</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Increased attrition occurring as a function of trial length</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karl Rickels, M.D.</name_or_title>
      <organization>UPENN</organization>
      <phone>215-746-6417</phone>
      <email>krickels@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

